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Novelty and Impact 
Results from the present study support a role for IKKα in the progression of ER-positive 
breast cancer.  For the first time this study demonstrates that increased levels of IKKα are 
associated with reduced recurrence-free survival on tamoxifen and reduced cancer specific 
survival. Furthermore, in ER-positive cells reduction of IKKα induced apoptosis and 
decreased cell viability.  This study provides for the first time, evidence for IKKα as a 
possible target in endocrine treated breast cancer. 
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Abstract 
The aim of the current study was to examine the relationship between tumour IKKα 
expression and breast cancer recurrence and survival.  Immunohistochemistry was employed 
in a discovery and a validation tissue microarray to assess the association of tumour IKKα 
expression and clinico-pathological characteristics.  Following siRNA-mediated silencing of 
IKKα, cell viability and apoptosis were assessed in MCF7 and MDA-MB-231 breast cancer 
cells.  In both the discovery and validation cohorts, associations observed between IKKα and 
clinical outcome measures were potentiated in oestrogen receptor (ER) positive Luminal A 
tumours.  In the discovery cohort, cytoplasmic IKKα was associated with disease-free 
survival (P=0.029) and recurrence-free survival on tamoxifen (P<0.001) in Luminal A 
tumours. Nuclear IKKα and a combination of cytoplasmic and nuclear IKKα (total tumour 
cell IKKα) were associated with cancer-specific survival (P=0.012 and P=0.007, 
respectively) and recurrence-free survival on tamoxifen (P=0.013 and P<0.001, respectively) 
in Luminal A tumours.  In the validation cohort, cytoplasmic IKKα was associated with 
cancer-specific survival (P=0.023), disease-free survival (P=0.002) and recurrence-free 
survival on tamoxifen (P=0.009) in Luminal A tumours.  Parallel experiment with breast 
cancer cells in vitro demonstrated the non-canonical NF-κB pathway was inducible by 
exposure to lymphotoxin in ER-positive MCF7 cells and not in ER-negative MDA-MB-231 
cells. Reduction in IKKα expression by siRNA transfection increased levels of apoptosis and 
reduced cell viability in MCF7 but not in MDA-MB-231 cells. IKKα is an important 
determinant of poor outcome in patients with ER-positive invasive ductal breast cancer and 
thus may represent a potential therapeutic target. 
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Introduction 
Breast cancer is the most common female cancer in the UK and remains the second most 
common cause of cancer death in women despite earlier detection and improved treatments.  
Oestrogen receptor (ER)-positive tumours can be effectively treated with tamoxifen and 
other endocrine therapies, however endocrine resistance remains a major clinical problem 1.  
The Gap Analysis Working Group identified molecular mechanisms driving resistance to 
treatment as one of the top 10 gaps in research that if addressed would make the most 
clinical impact 2.  Studies have demonstrated that 30% of patients with Luminal A disease 
and 90% of patients with Luminal B exhibit high recurrence scores 3, 4. 
The Nuclear Factor kappa B (NF-κB) family of transcription factors has five members 
(p105/50 (NF-B1), p100/52 (NF-B2), p65 RELA, RelB, c-REL) involved in two main 
pathways, the canonical and non-canonical pathways 5.  Upon activation of the non-
canonical NF-B pathway, the NF-B-inducing kinase (NIK) phosphorylates IKKα which in 
turn phosphorylates p100 to identify it for ubiquitination and targeted proteolytic processing 
subsequently generating p52 and allowing the liberation of active p52/RelB dimers 6.  These 
complexes translocate to the nucleus and regulate transcription of a variety of genes 
important in apoptosis, proliferation, invasion and adaptive immunity 7-9.  Therefore it is not 
surprising that studies have demonstrated dysregulation of the non-canonical NF-B 
pathway in many solid tumours 10, 11.  More recently the non-canonical NF-κB pathway has 
been implicated in the development and progression of breast cancer 12. Oestrogen inhibits 
the Notch pathway and application of anti-oestrogens result in the activation of Notch 13 and 
the kinase activity of IKKα has been found to be associated with Notch in the activation of 
ER-dependent genes 14. In mice a delay in mammary gland development is observed when 
p100/52 is overexpressed and these mice developed multiple tumours 15, however other 
information is lacking.  The current study aims to assess if members of the non-canonical 
 5 
NF-ĸB pathway are associated with clinical outcome measures in breast cancer patients. 
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Materials and methods 
Patient cohorts 
This retrospective study used previously constructed tissue microarrays (TMAs) made from 
formalin-fixed paraffin-embedded tissue (FFPE) blocks retrieved from pathology archives. A 
consultant pathologist identified tumour rich areas, and three different 0.6mm2 cores were 
lifted from these areas and placed into new blocks. Ethical approval for the use of this tissue 
was granted by the Research Ethics Committee of the North Glasgow University Hospitals 
NHS Trust (NHS GG&C rec no 10/50704/60). 
The discovery cohort TMA included 362 breast cancer patients presenting with invasive 
ductal breast cancer in the West of Scotland (at Glasgow Royal Infirmary, Glasgow Western 
Infirmary and Stobhill Hospital), between 1995 and 1998. Patients were excluded if follow-
up was incomplete or tumour tissue was insufficient.  Clinico-pathological data available 
included age, tumour grade, tumour size, lymph node status, therapy, ER, PgR and HER2 
status and Ki67 proliferation index. Information on inflammatory infiltrate and tumour 
microenvironment had previously been established for the cohort 16-28. 
IHC for IKKα was performed on a validation cohort of ER-positive patients. This TMA and 
clinical database included 266 ER-positive patients presenting with invasive ductal breast 
cancer between 1980 and 1995 from Glasgow Royal Infirmary.  Clinico-pathological data 
available included age, tumour grade, tumour size, lymph node status, therapy, PgR and 
HER2 status and Ki67 proliferation index 29-32. All patients in this cohort were treated with 
adjuvant tamoxifen. 
Immunohistochemistry 
Immunohistochemistry (IHC) was performed to assess protein levels of RelB, NIK and 
IKKα; components of the non-canonical NF-κB pathway. TMA sections (2.5µm thick) were 
dewaxed by immersion in xylene and rehydrated through a series of graded alcohols. Heat 
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induced antigen retrieval was performed in a solution of citrate buffer pH6. Tissue was then 
incubated in 3% (v/v) hydrogen peroxide before non-specific binding was blocked by 
incubation in either 5% (v/v) normal horse serum solution (Vector Laboratories; IKKα, 
RelB) or 1x caesin solution (Vector Laboratories; NIK). Slides were then incubated in 
primary antibody overnight at 4°C at optimal concentration of antibody diluted in antibody 
diluent (Dako). The primary antibodies and concentrations used are as follows: anti-RelB 
(4954, Cell Signaling) was used at 1:75, anti-NIK (S2622, Epitomics) at 1:250, and anti-
IKKα (GWB-662250, Genway) at 1:1000. Staining was developed using EnVision™ (Dako) 
and 3,3’-diaminobenzidine (DAB, Vector Laboratories). Harris Haematoxylin 
counterstaining was performed and tissue was dehydrated and mounted using DPX.  
Supplementary Figure 1 provides examples of high and low IKKα staining.  Antibodies were 
validated by western blotting and IHC, for the anti- IKKα antibody, a single band of the 
predicted molecular weight (85kDa) was observed on a western blot.  Cells were pre-treated 
with 200 nM siRNA against either IKKα or IKK to check specificity for IKKα.  A 
reduction in expression was observed in IKKα silenced but not IKK silenced cells as 
assessed by western blotting of cell lysates and IHC of cell pellets (supplementary figure 2). 
Stained TMA sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden 
City, Hertfordshire, UK) at x20 magnification and visualization was carried out using 
Slidepath Digital Image Hub, version 4.0.1 (Slidepath, Leica Biosystems, Milton Keynes, 
UK).  Protein expression was assessed using the weighted histoscore method [LB], with a 
second independent observer [JE] scoring 10% of cores and the interclass corRelation 
coefficient (ICCC) calculated to ensure no observer bias 33.  Cytoplasmic and nuclear 
expression were calculated separately. 
Cell culture 
MCF7 (ER-positive) and MDA-MB-231 (ER-negative) breast cancer cells were routinely 
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cultured in 5% CO2 at 37°C in Dulbecco’s Modified Eagle Medium (DMEM, Life 
Technologies) with 10% (v/v) Fetal Bovine Serum (FBS, Sigma-Aldrich), 10 Units/ml 
Penicillin/Streptomycin (Life Technologies) and 1x GlutaMAX™ (Life Technologies). 
Ligand exposure 
Cells were seeded in 12 well plates at 1x105 cells per well and once 70% confluent were 
rendered quiescent by incubation in serum free media for 24hours and exposed to 20ng/ml 
lymphotoxin α1β2 (LTx, Sigma-Aldrich) for 4 hours, 8 hours and 24 hours to stimulate the 
non-canonical pathway.  
Western blotting 
After exposure to the LTx or siRNA, cells were lysed in pre-heated Laemmli’s sample buffer  
and SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) was performed using resolving 
gels.  Proteins were then transferred to nitrocellulose membranes by electrophoretic blotting 
in wet conditions and non-specific binding blocked by incubation in a solution of 3% (w/v) 
BSA in NaTT buffer. Membranes were incubated overnight, either at room temperature or 
4°C, in primary antibody specific to the target protein diluted to optimal concentration in 
NaTT buffer containing 0.3% (w/v) BSA. Antibodies and dilutions used were as follows: 
IKKα (1:3500, OP133, Calbiochem), p100/52 (1:3000, 05-361, Millipore), phospho-p100 
(1:2000, 4810, Cell Signaling). β-tubulin was used (1:5000, ab21058, Abcam) as a loading 
control. 
Membranes were washed for 1h 30min with NaTT, changed every 15 min, and then were 
incubated in secondary HRP-conjugated antibody (either rabbit or mouse, depending on 
primary antibody) diluted 1:10000 for 1h 30min and then washed again as per previous. 
Enhanced chemiluminescence (ECL) reagent (1:1 mixture of solution 1 [1M Tris pH8.5, 
250mM luminol, 250mM p-cymuric acid and water] and solution 2 [1M Tris pH8.5, 0.19% 
H2O2 and water]) was used to develop and X-ray films developed using an X-OMAT 
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machine (Kodak) or the SynGene imaging system. Images were quantified using ImageJ 
with protein expression normalised to the β-tubulin loading control and expression compared 
to untreated cells, calculated as fold change to control. Statistical analysis was performed 
using a one-way ANOVA with Bonferroni correction and Dunnett’s test to compare to 
control levels. 
 
siRNA-mediated Silencing of IKK 
In order to observe the impact of loss of cellular IKKα expression on cellular viability, 
MCF7 and MDA-MB-231 cells were transfected with ON-TARGETplus siRNA (Thermo 
Scientific) against sequences for IKKα (CHUK, #J-003473-09) and non-targeting sequence 
(NT) was used as a negative control (Non-targeting #1, #D-001810-01-20). Lipofectamine® 
RNAiMAX (Life Technologies) diluted in Opti-MEM® (Life Technologies) was used to 
deliver the siRNA to the cells. After 6 hours media was replaced with normal  DMEM 
containing 10% (v/v) FCS and after 48 hours protein lysis and analysis via Western blotting 
was performed, or a functional assay was applied to assess apoptosis or viability. 
Apoptosis and cell viability assays 
We employed the use of RNA interference to observe the effect a decrease in expression of 
IKKα had on cell growth and viability in MCF7 and MDA-MB-231 cells.  MCF7 and MDA-
MB-231 cells were transfected with 200nM NT siRNA or 200nM IKKα siRNA. These cells 
were then seeded for use in apoptotic assays, wst-1 assays and western blotting.  The western 
blot was used to ensure a decrease in expression of IKKα had been achieved in the cells used 
for the apoptotic and cell viability assays. Forty eight hours post treatment, apoptotic and cell 
viability assays were performed and cells lysed for western blot analysis.  This method 
ensured that the cells used in both the assays were from the same population.   Cells were 
assessed for apoptosis levels using a Cell Death Detection enzyme-linked immunosorbent 
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assay kit (Roche) and for cell viability using the water-soluble tetrazolium salt (WST-1) 
reagent (Roche). Cells were seeded in 96 well plates at a density of 5x103 cells/well in 100μL 
of standard culture medium. Once a confluency of 60-70% was reached cells were exposed 
to siRNA for 48 hours and the assays then performed following manufacturer’s instructions. 
Assays were performed in triplicate and error bars representing standard deviation added to 
graphs.  
Cell viability via xCELLigence 
The xCELLigence machine (ACEA Biosciences, San Diego) was used to display cell growth 
and viability in real time following silencing of IKKα. With this method, measurements are 
continuously sent to the computer, allowing for real time growth curves to be plotted using 
“Cell Index” which represents the number and viability of the cells. Cells were seeded in a 
96 well E-plate™ (ACEA Biosciences, San Diego) at 3x103 cells/well with 200l of media 
in each well, grown for two days to ensure log phase growth before treatment with siRNA 
and after 72 hours graphs showing cell index over time were drawn. 
Taqman low density arrays (TLDA) 
As the biggest effect on phenotypic output was observed for apoptosis in ER-positive MCF7 
cells, 384 TLDA gene signature apoptosis arrays containing 93 genes Related to apoptosis 
and 3 candidate endogenous controls were employed to investigate the change in gene 
profile following siRNA-mediated silencing (NT or IKKα ). After 48 hour silencing 
incubation, the media was replaced with serum free media for 12 hours to rendered quiescent 
followed by LTx stimulation for 12 hours. Thus, the total time for silencing and LTx 
treatment was 72 hours.  RNA was extracted using an RNeasy mini kit following 
manufacturer’s protocol with DNase digestion performed on the column (Qiagen). 
Preparation of cDNA and RT-PCR were performed using TaqMan RT-PCR methodology 
and reagents (Perkin-Elmer Applied Biosystems). TLDA gene arrays containing 93 genes 
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and 3 candidate endogenous controls were employed to determine if IKK silencing induced 
change in expression of genes (supplementary Table 1). Each sample from 3 independent 
silencing experiments on MCF7 cells was run in duplicate. All results were analyzed 
simultaneously by RQ Manager Software (ABI, UK) and the threshold cycle (Ct) values for 
the genes of interest were calibrated against 18S Ct (dCt).  
Statistical Analysis 
Statistics were performed using IBM SPSS version 21.  Kaplan-Meier curves were 
constructed for cancer-specific survival and the log rank test was employed to compare high 
and low expression. Hazard ratios were calculated using Cox regression with 95% 
confidence intervals. Cox regression multivariate analysis was also performed with the 
inclusion of known predictive factors.  Inter-Relationships between variables were assessed 
using contingency tables with the chi-squared test for trend as appropriate.  Values of P<0.05 
were considered statistically significant.  Statistical analysis for Western blots, apoptosis and 
cell viability assays was performed using a one-way ANOVA with Bonferroni correction 
and Dunnett’s test. P values were considered significant if P<0.05 and highly significant if 
P<0.001.  TLDA card raw data were analysed using Quantstudio 7 with the following 
settings: 1) automatic baseline 2) threshold = 0.2. Ct values over 32 were defined as 
undetectable. Significant changes in gene expression were defined with a P-value boundary 
of 0.05. Results are presented as a volcano plot. 
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Results 
IKKα expression is associated with poor prognosis in breast cancer 
Discovery cohort:  
A total of 362 patients who presented with invasive ductal breast cancer were included in the 
study.  ER, PgR, HER2 and Ki67 status were available allowing determination of the tumour 
subtype, 46% (165) of patients had Luminal A disease (ER or PgR-positive, HER2-negative 
and low Ki67 <14%), 22% (81) had Luminal B disease (ER- or PgR- and HER2-positive or 
ER, PgR and high Ki67 (>14%)), 20% (72) had triple negative disease (ER-, PgR- and 
HER2-negative) and 10% (38) had HER2 enriched (ER- and PgR-negative, HER2-positive).  
We were unable to define subtype in 2% (6) of cases due to missing data.   
Expression of IKKα was observed in the tumour cell cytoplasm and nucleus (median 
expression 100, interquartile range 69-140 and median expression 126, interquartile range 
73-115, respectively).  NIK expression was observed in the tumour cell cytoplasm (median 
expression 100, interquartile range 69-140) and RelB expression was observed in the tumour 
cytoplasm and the nucleus (median expression 113, interquartile range 90-146 and median 
expression 0, interquartile range 0-7, range 0-190, respectively).  No correlations were 
observed between NIK expression and expression of IKKα in any cellular location 
investigated. Expression of cytoplasmic IKKα correlated with cytoplasmic and total tumour 
cell RelB (P=0.005 and P=0.003, respectively), nuclear IKKα correlated with nuclear and 
total tumour cell RelB (P<0.001 and P<0.001, respectively) and total tumour cell IKKα 
correlated with cytoplasmic, nuclear and total tumour cell RelB expression (P=0.010, 
P=0.004 and P<0.001, respectively). 
Eighty four patients had local or distant recurrence, the median follow-up of survivors was 
164 months with 76 cancer-associated deaths and 77 non-cancer deaths.  Expression of NIK 
or RelB was not associated with cancer-specific survival, disease-free survival or recurrence-
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free survival on tamoxifen, in the full patient cohort or when stratified by tumour subtype 
(Table 1 and Table 2).   
High cytoplasmic IKKα was not associated with cancer-specific survival in the full cohort 
(Table 1), however was significantly associated with shorter disease-free survival (Table 
1)(P=0.045) and recurrence-free survival on tamoxifen (Table 1)(P=0.003).  5 year disease-
free survival was reduced from 88% (low) to 79% (high) (P=0.039) and recurrence-free 
survival on tamoxifen was reduced from 73% (low) to 25% (high) (P=0.019). 
When stratified by tumour subtype, high cytoplasmic IKKα expression showed a non-
significant trend towards shorter cancer-specific survival (Figure 1A; P=0.076), a significant 
association with shorter disease-free survival (Figure 1B;  P=0.029) and a significant 
association with shorter recurrence-free survival on tamoxifen (Figure 1C; P<0.001) in 
Luminal A tumours.  5 year disease-free survival was reduced from 99% (low) to 89% (high) 
(P=0.011) and recurrence-free survival on tamoxifen was reduced from 94% (low) to 30% 
(high) (P<0.001).   
The relationship between cytoplasmic IKKα and tumour characteristics was examined.  High 
expression of cytoplasmic IKKα was associated with tumour size (P=0.032), tumour grade 
(P=0.009), ER-positive disease (P=0.002), HER2-positive disease (P=0.023) and tumour 
subtype (P<0.001).  When associations with the tumour microenvironment were 
investigated, cytoplasmic IKKα was not significantly associated with tumour stroma 
percentage (TSP) or tumour budding.  However an association was observed with necrosis 
(P=0.009) and local inflammatory cell infiltrate as assessed by Klintrup-Makinen grade 
(P=0.005). 
High nuclear IKKα was not associated with cancer-specific survival, disease-free survival or 
recurrence-free survival on tamoxifen in the full cohort (Table 1).  However when stratified 
by tumour subtype, high nuclear IKKα expression showed a significant association with 
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shorter cancer-specific survival (Figure 1D; P=0.012), a non-significant trend towards 
shorter disease-free survival (Figure 1E; P=0.066) and a significant association with 
recurrence-free survival on tamoxifen (Figure 1F; P=0.013) in Luminal A tumours.  10 year 
cancer-specific survival was reduced from 97% (low) to 87% (high) (P=0.013) and 
recurrence-free survival on tamoxifen was reduced from 100% (low) to 55% (high) 
(P=0.015).   
The relationship between nuclear IKKα and tumour characteristics was examined.  High 
expression of nuclear IKKα was associated with tumour grade (P=0.014), ER-positive 
disease (P=0.047), tumour subtype (P=0.042) and patient survival (P=0.008).  When 
associations with the tumour microenvironment were investigated, nuclear IKKα was not 
significantly associated with TSP or tumour budding.  However an association was observed 
with local inflammatory cell infiltrate as assessed by Klintrup-Makinen grade (P=0.016) and 
density of CD8+ T-lymphocytes (P=0.035). 
To examine the relationship of cancer-specific survival and total tumour cell expression of 
IKKα, a cumulative prognostic score of cytoplasmic and nuclear IKKα was examined (total 
tumour cell IKKα).  Patients with both high cytoplasmic and nuclear expression were 
classified as the high expression group and patients with either low cytoplasmic or nuclear 
expression were classified as the low expression group.  High expression of total tumour cell 
IKKα, was not associated with shorter cancer-specific survival or disease-free survival in the 
full cohort, but was associated with recurrence-free survival on tamoxifen (Table 1; 
P=0.011). Recurrence-free survival on tamoxifen was reduced from 79% (low) to 54% 
(high) (P=0.029).   
When stratified by tumour subtype, high total tumour cell IKKα expression showed a 
significant association with shorter cancer-specific survival (Figure 1G; P=0.007), shorter 
disease-free survival (Figure 1H; P=0.013) and recurrence-free survival on tamoxifen 
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(Figure 1I)(P<0.001) in Luminal A tumours.  10 year cancer-specific survival was reduced 
from 96% (low) to 83% (high) (P=0.006), 5 year disease-free survival was reduced from 
99% (low) to 86% (high)(P=0.001) and recurrence-free survival on tamoxifen was reduced 
from 94% (low) to 30% (high) (p<0.001).   
High expression of total tumour cell IKKα was only associated with density of CD8+ T-
lymphocytes (P=0.034) and not with any other tumour or microenvironment characteristics. 
In Luminal A tumours, when cytoplasmic, nuclear and total tumour cell IKKα were entered 
into a multivariate model using a backwards conditional method with clinic-pathological 
parameters, only nuclear IKKα remained independently associated with cancer-specific 
survival (HR=9.4, 95% CI=2.02-22.67, P=0.004, Table 2). 
Validation cohort: 
As the strongest associations were observed between IKKα and clinical outcome measures in 
patients with Luminal A tumours in the discovery cohort, this was investigated in an 
independent ER-positive validation cohort.  A total of 266 patients who presented with ER-
positive invasive ductal breast cancer were included in the study.  ER, PgR, HER2 and Ki67 
status were available for these patients allowing us to determine the tumour subtype. 76% 
(201) of patients had Luminal A disease and 21% (56) had Luminal B disease.  We were 
unable to define subtype in 3% (9) of cases due to missing data.    
Expression of IKKα was observed in the tumour cell cytoplasm within a similar range to that 
observed for the ER-positive tumours in the discovery cohort (discovery cohort: median 
expression, 96 interquartile range 61-130, validation cohort: median expression 96, 
interquartile range 73-120).  However expression in the nucleus between the cohorts was not 
similar (discovery cohort: median expression 133, interquartile range 80-180, validation 
cohort: median expression 33, interquartile range 15-60).   
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Seventy four patients had local or distant recurrences, the median follow-up of survivors was 
96 months with 69 cancer-associated deaths and 58 non-cancer deaths.  As was previously 
observed in discovery cohort, high cytoplasmic IKKα was not associated with cancer-
specific survival and was significantly associated with shorter disease-free survival (Figure 
2A; P=0.024) and recurrence-free survival on tamoxifen (Figure 2B; P=0.038) in the 
validation cohort.  
When stratified by tumour subtype, high cytoplasmic expression of IKKα showed a 
significant association with shorter cancer-specific survival (Figure 2C; P=0.023), shorter 
disease-free survival (Figure 2D; P=0.002) and recurrence-free survival on tamoxifen 
(Figure 2E; P=0.009) in Luminal A tumours.  10 year cancer-specific survival was reduced 
from 80% (low) to 62% (high) (P=0.005), 5 year disease-free survival was reduced from 
87% (low) to 64% (high) (P=0.004) and recurrence-free survival on tamoxifen was reduced 
from 84%(low) to 66% (high) (P=0.027).   
High expression of cytoplasmic IKKα was associated with tumour grade (P=0.009) as 
previously observed for discovery cohort. We were unable to assess associations with IKKα 
and the tumour microenvironment as these parameters were not available for analysis for the 
validation cohort. 
In Luminal A tumours, when cytoplasmic IKKα was entered into a multivariate model using 
a backwards conditional method with size, grade and nodal status, parameters, cytoplasmic 
IKKα remained independently associated with cancer-specific survival (HR=2.03, 95% 
CI=1.06-3.87, P=0.031). 
In the validation cohort nuclear IKKα and total tumour cell IKKα were not associated with 
cancer-specific survival, disease-free survival or recurrence-free survival on tamoxifen in the 
full cohort or in Luminal A tumours. 
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IKKα silencing is associated with reduced cell viability and induction of apoptosis in 
ER-positive breast cancer cells 
We observed that IKKα expression is associated with poor prognosis in breast cancer 
patients, and this is potentiated in the ER-positive Luminal A subtype.  Therefore the next 
aim of the study was to establish if IKKα could offer a novel therapeutic target for treatment 
of breast cancer.  MCF7 cells were chosen to represent ER-positive breast tumours and 
MDA-MB-231 were chosen to represent ER-negative breast tumours.   
Both cell lines were treated with lymphotoxin (LTx), a ligand known to stimulate the non-
canonical NF-B pathway. In ER-positive MCF7 cells LTx significantly increased p52 
expression on average 2.1 fold after 24 hours (Figure 3A)(P=0.049). An increase in p100 
phosphorylation was clearer with an increase at 8 hours LTx exposure (Figure 3A) (P=0.024) 
and peak expression at 24 hours exposure with an average 8.8 fold increase compared to 
untreated MCF7 cells (Figure 3A) (P=0.005).  
In ER-negative MDA-MB-231 cells constitutive expression of phospho-p100 was observed, 
with little difference between control and cells exposed to LTx (Figure 3A). Additionally, no 
significant increase in p52 was evident with LTx exposure at any time point (Figure 3A). 
Using a lipofection based method, siRNA was delivered to the cells to reduce expression of 
IKKα.  After 48 hours incubation siRNA targeted to IKKα effectively reduced expression of 
IKKα at all concentrations in both cell lines (Figure 3B).   
MCF7 and MDA-MB-231 cells were transfected with 200nM IKKα siRNA, as well as non-
targeting (NT) siRNA, and 48 hours post treatment the apoptosis assay was performed. 
Serum starvation, which induces apoptosis, was used as an additional control. ER-positive 
MCF7 cells treated with NT siRNA did not show a significant difference in apoptosis when 
compared to untreated control cells (Figure 3C) (P=0.992). A significant increase was 
observed in levels of apoptosis when cells were treated with siRNA to silence expression of 
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IKKα (Figure 3C) (P=2.5x10-5). ER-negative MDA-MB-231 cells treated with either NT or 
IKKα siRNA did not show a significant difference in apoptosis when compared to untreated 
control cells (Figure 3C) (both P=1.0). 
Cell viability was also assessed in both MCF7 and MDA-MB-231 cells following siRNA-
mediated silencing of IKKα for 48 hours. In MCF7 cells treated with NT siRNA, cell 
viability was not significantly different to untreated control cells (Figure 4A; P=0.550). A 
decrease in cell viability was observed when cells were treated with siRNA to silence 
expression of IKKα (Figure 4A; P=0.001). In MDA-MB-231 cells, cell viability was not 
significantly different in cells treated with NT or IKKα siRNA in comparison to untreated 
control cells (Figure 4A; P=0.952 and P=0.889, respectively). 
Cell viability was also measured using the xCELLigence platform.  In MCF7 ER-positive 
cells NT siRNA did not appear to be different to that observed for untreated cells but siRNA 
to silence expression of IKKα reduced cell viability (Figure 4B). In MDA-MB-231 cells 
neither NT nor IKKα siRNA displayed any difference in cell viability compared to untreated 
cells (Figure 4B).  
As the associations with cell viability were only observed in ER-positive MCF7 cells and the 
strongest association being for apoptosis, TLDA apoptotic signature gene cards were 
employed to examining changes in gene expression as a result of IKKα silencing in these 
cells.  The results are displayed as a volcano plot (Figure 4C).  Fourteen genes induced by 
LTx treatment were noted to change significantly in response to IKKα siRNA (CHUK, 
BAK1, BBC 3, CRADD, BCL 10, RIPK2, TNFSF10, FAS, BIRC3, CASP8, NFKBIA, 
CASP3, CFLAR and TNFRSF2) (Figure 4C).  CHUK (IKKα) was used as an internal 
control to demonstrate that silencing had been effective. The pro-apoptotic genes BAK and 
BBC3 showed the greatest fold change increase across the 3 experiments. 
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Discussion 
In the current study immunohistochemistry was employed to assess expression/levels of 
NIK, RelB and IKKα in a discovery cohort and establish associations with clinico-pathologic 
parameters. NIK and RelB were not associated with cancer-specific survival, disease-free 
survival or recurrence-free survival on tamoxifen in the full cohort or when stratified by 
tumour subtype as determined by ER, Pgr, HER2 and Ki67 status.   Breast cancer can be 
stratified into 4 molecular subtypes (Luminal A, Luminal B, triple negative and HER2 
enriched) bases on gene profiling, however it is now widely accepted that tumours can now 
be classified into tumour subtypes using a panel of 4 biomarkers (ER, PgR, Ki67 and 
HER2), and although not true representatives of molecular subtype, do represent tumour 
subtypes with different patient prognosis, therefore in this study although when tumour 
subtype is referred to it is on the basis of ER, PgR, HER2 and Ki67 status and not molecular 
subtypes as defined by gene profiling. 
In the current study although NIK and RelB are not associated with patient recurrence or 
survival, in contrast levels of IKKα expression were associated with disease-free survival in 
the full cohort and when the cohort was stratified by subtype.  Associations between patient 
outcome measures were completely negated in the Luminal B subtype, but potentiated in the 
ER-positive Luminal A subtype. Luminal A subtype is the most common subtype in this 
patient cohort, therefore it could be possible that this observation is due to the Luminal A 
group being the only appropriately powered subtype in this cohort.  However no trends were 
observed for patients with Luminal B, triple negative or HER2 enriched subtypes, providing 
weight to the argument that the associations observed were only observed in patients with 
Luminal A tumours.   
As it is only IKKα that is associated with patient outcome and not expression levels of NIK 
or RelB, it is probable that activation status of NIK and RelB are required to be measured to 
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demonstrate activation of the pathway, however as there are inherent problems associated 
with phosphorylated antibodies we propose IKKα is a more robust marker to be employed.   
An alternative explanation is IKKα has a role independent of the non canonical pathway, 
however the current study has no conclusive evidence to support this theory.  Recently work 
in colorectal cancer and cutaneous squamous cell carcinoma has demonstrated a role for 
IKKα independent of the non-canonical NF- B pathway 10, 34-36 and this been suggested to 
be via a truncate form of IKKα (p45 IKKα) that is constitutively active and specifically 
resides in the nucleus 10. In the discovery cohort, when Luminal A tumours were considered 
only nuclear IKKα remained independently associated with cancer-specific survival.   This 
suggests that nuclear IKKα expression had a stronger predictive power than total tumour cell 
IKKα, and could be due to detection of the truncated activated form of IKKα.  However, this 
observation was not upheld in the validation cohort, as it was only cytoplasmic IKKα that 
remained associated with prognosis, suggesting it is more likely that cytoplasmic IKKα is a 
better marker of non canonical pathway activation, and nuclear truncated IKKα does not play 
a strong role. 
Taken in combination, these results suggest irrespective of cellular location that IKKα plays 
an important role in the progression of breast cancer, as cytoplasmic, nuclear and total 
tumour cell expression of IKKα were all associated with clinical outcome measures in 
patients with Luminal A disease. 
Due to the associations of IKKα expression with clinical outcome measures in patients with 
Luminal A disease, IKKα was assessed in a second validation cohort, of 266 women with 
ER-positive breast cancers, all of whom received tamoxifen therapy.  This cohort, provided 
greater power for investigating associations with recurrence-free survival on tamoxifen.  In 
the validation cohort, cytoplasmic IKKα expression levels were observed at very similar 
levels to that of the discovery cohort.  However nuclear IKKα expression in the validation 
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cohort was at a much lower level than that of the discovery cohort.  The reason for this was 
unclear as the same antibody and immunohistochemical protocol were employed across both 
studies.  One possible explanation is that the second cohort was older therefore may have 
been subject to different fixation methods or storage or that nuclear IKKα is more prone to 
degradation than cytoplasmic IKKα.  As a result of the differing nuclear expression levels, 
the same cut offs for nuclear IKKα to determine high and low expression could not be 
employed across both cohorts.  Even when median values of nuclear IKKα from the 
validation cohort were used, the results obtained in the discovery cohort were not replicated. 
In contrast we were able to validate the results observed in the discovery cohort for 
cytoplasmic IKKα expression in the validation cohort.  Once again cytoplasmic IKKα was 
observed to be associated with disease-free survival and recurrence-free survival on 
tamoxifen in the full validation cohort, and this observation was potentiated in patients with 
Luminal A disease.  Taken together the results from both cohorts suggest that cytoplasmic 
IKKα is a more robust marker than nuclear IKKα and may be employed as a prognostic 
marker in Luminal breast cancer to predict patients likely to develop resistance to tamoxifen 
or IKKα targeted therapies.   
Preliminary experiments were performed to investigate if targeting IKKα offered a possible 
therapeutic target in breast cancers. IKKα expression was suppressed using siRNA and cell 
viability assessed.  Decreased cell growth and viability can reflect either a reduction in 
proliferation rates or an increase in apoptosis, or a combination of both mechanisms. Cell 
viability was measured through various methods including assessment of apoptosis using an 
ELISA, viability using a WST-1 assay, real-time growth and viability using xCELLigence. 
The effect of silencing IKKα on phenotypic outputs was examined in both ER-positive 
MCF7 cells and ER negative MDA-MB-231 cells, to establish if a difference was observed 
between ER status as was observed in the patient tissue samples.  In keeping with results 
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from the clinical specimens, IKKα silencing only had an impact in ER-positive MCF7 breast 
cancer cells and not on ER-negative MDA-MB-231 cells.  In addition, gene card 
experiments demonstrated that reducing IKKα expression had a significant impact on 
increased expression of genes associated with induction of apoptosis, in particular BAK1 and 
BBC3.  This is in keeping with previous reports that demonstrate that both BAK1 and BBC3 
are associated with prognosis and or response to therapy in breast cancer 37-39.  It therefore 
appears that IKKα selective inhibitors would be most beneficial to patients with ER-positive 
tumours and may function via induction of apoptosis and inhibition of proliferation.  Studies 
from the literature demonstrate that IKKα is involved in regulation of oestrogen-dependent 
genes such as cyclin D1 and c-myc, resulting in increased proliferation 6.   However future 
studies in a large panel of ER positive and ER negative cell lines are required to confirm this 
observation.  Future studies should also investigate impact of tamoxifen treatment and 
resistance to tamoxifen in cell line studies.    
The results from both the tissue and in vitro work from the current study demonstrate that 
IKKα is associated with regulation of ER-positive breast cancer, suggesting inhibitors of 
IKKα would be beneficial for breast cancer patients. Exploiting IKKα as a target may offer 
additional therapeutic options following development of endocrine resistance 2. Additional 
thorough investigation, including both larger tissue studies and mechanistic work, is required 
to further elucidate the role of IKKα in the progression of breast cancer, though involvement 
of IKKα in breast cancer recurrence is clearly apparent. Once novel compounds are found to 
be selective and efficient in preclinical models, inhibitors of IKKα may therefore provide a 
promising therapeutic approach in the future for breast cancer, particularly in patients who 
develop endocrine resistance.  
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Table 1: 
The relationship between clinico-pathological characteristics, members of the non canonical NFB and 
cancer specific survival, disease-free survival and recurrence on tamoxifen in patients with invasive 
ductal breast cancer  
Full cohort  Cancer-specific 
survival 
Disease-free s 
survival 
Recurrence on 
Tamoxifen 
 P-value 
(n=362) 
P-value 
(n=344) 
P-value 
(n=65) 
Age (<50/>50 years) 0.275 0.436 0.743 
Size (≤20/21-50/>50 mm) 0.001 0.009 0.733 
Grade (I/II/III) <0.001 <0.001 0.020 
Involved lymph node 
(no/yes) 
<0.001 <0.001 0.043 
ER status (no/yes) 0.002 <0.001 NA 
PR status (no/yes) <0.001 <0.001 0.154 
HER2 status (no/yes) 0.002 <0.001 0.065 
Tumour subtype(Luminal 
A/Luminal B/triple negative, 
HER2 enriched) 
<0.001 <0.001 0.001 
Tumour necrosis (low/high) <0.001 <0.001 0.003 
Lymph vessel invasion 
(no/yes) 
<0.001 <0.001 0.001 
Blood vessel invasion 
(no/yes) 
<0.001 0.003 0.719 
Klintrup–Mäkinen grade 
(week/strong) 
0.180 0.223 0.775 
CD68+ (low/moderate/high) 
0.321 0.325 0.096 
CD4+ (low/moderate/high) 
0.428 0.942 0.823 
CD8+ (low/moderate/high) 
0.005 0.028 0.046 
CD138+(low/moderate/high) 
0.555 0.117 0.533 
Angiogenesis 
(low/moderate/high) 
0.094 0.025 0.574 
Tumour stroma percentage 
(low/high) 
<0.001 0.001 0.777 
Tumour budding (low/high) 
0.002 0.164 0.535 
Cyto IKKα (low/high) 
0.264 0.045 0.003  
Nuclear IKKα (low/high) 
0.143 0.555 0.123 
Total tumour cell  IKKα(one 
low/both high) 
0.883 0.504 0.011 
Cyto NIK(low/high) 
0.155 0.390 0.765 
Cyto RELB (low/high) 0.511 0.495 0.319 
Nuclear RELB (low/high) 
0.304 0.254 0.972 
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Bold indicates a significant association  
Total tumour cell RELB  
(one low/both high) 
0.349 0.500 0.774 
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Table2: 
The relationship between clinico-pathological characteristics, members of the non-canonical NFB and cancer specific survival 
in patients with Luminal A invasive ductal breast cancer  
 Univariate analysis Multivariate analysis 
Patients (n=165) Hazard ratio (95% CI)         P-
value 
  Hazard ratio (95% CI) P-value 
Age (<50/>50 years) 2.44(0.54-10.93) 0.227   
Size (≤20/21-50/>50 mm) 1.38(0.53-3.61) 0.555   
Grade (I/II/III) 1.41(0.61-3.25) 0.262   
Involved lymph node (no/yes) 1.24(0.41-3.71) 0.692   
PgR status (no/yes) 0.30(0.10-0.88) 0.020 0.31(0.10-0.92) 0.035 
Tumour necrosis (low/high) 3.01(1.09-9.2) 0.042   
Lymph vessel invasion (no/yes) 1.59(0.53-4.74) 0.401   
Blood vessel invasion (no/yes) 
4.02(1.26-12.83) 0.011 6.3(1.89-21.3) 0.003 
Klintrup–Mäkinen grade (week/strong) 
0.04(0-56.64) 0.117   
CD68+ (low/moderate/high) 
0.81(0.39-1.67) 0.375   
CD4+ (low/moderate/high) 
0.78(0.40-1.51) 0.682   
CD8+ (low/moderate/high) 
0.65(0.32-1.30) 0.365   
CD138+(low/moderate/high) 
0.89(0.47-1.69) 0.937   
Angiogenesis (low/moderate/high) 
1.84(0.90-3.72) 0.211   
Tumour stroma percentage (low/high) 
4.02(1.25-12.88) 0.011 4.98(1.53-16.21) 0.008 
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Bold indicates a significant association 
Tumour budding (low/high) 
2.04(0.71-5.90) 0.175   
Cytoplasmic IKKα (low/high) 
2.59(0.87-7.74) 0.076   
Nuclear IKKα (low/high) 
5.48(1.22-24.53) 0.012 9.4(2.02-22.67) 0.004 
Total tumour cell IKKα (one low/both 
high) 
1.99(1.15-3.44) 0.007   
Cytoplasmic NIK (low/high) 
0.86(0.27-2.73) 0.810   
Cytoplasmic RELB (low/high) 0.80(0.25-2.49) 0.703   
Nuclear RELB  (low/high) 
0.66(0.180-2.45) 0.536   
Total tumour cell RELB (one low/both 
high) 
0.68(0.24-1.91) 0.541   
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Supplementary Table 1: 
Genes on TLDA Card 
 
  
Assay  Gene Symbol 
Hs00236911_m1 BIRC2 
Hs00832876_g1 BAK1 
Hs00180403_m1 BCL3 
Hs00354836_m1 CASP1 
Hs00892481_m1 CASP2 
Hs00362072_m1 CASP5 
Hs00169152_m1 CASP7 
Hs01018151_m1 CASP8 
Hs00154260_m1 CASP9 
Hs00395088_m1 IKBKB 
Hs99999901_s1 18S 
Hs00242739_m1 LTB 
Hs00172036_m1 MCL1 
Hs00765730_m1 NFKB1 
Hs00174517_m1 NFKB2 
Hs00182115_m1 NFKBIB 
Hs00234431_m1 NFKBIE 
Hs00560402_m1 PMAIP1 
Hs00232399_m1 RELB 
Hs00153550_m1 TNFRSF1B 
Hs00269492_m1 TNFRSF10A 
Hs00196075_m1 CARD4 
Hs00248187_m1 NALP1 
Hs00201637_m1 CASP14 
Hs00209789_m1 BCL2L13 
Hs00205419_m1 TNFRSF21 
Hs00376860_g1 HTRA2 
Hs00179410_m1 TBK1 
Hs00215973_m1 ESRRBL1 
Hs00388035_m1 LRDD 
Hs00223394_m1 CARD15 
Hs00364485_m1 CARD9 
Hs00230071_m1 NFKBIZ 
Hs00373302_m1 BCL2L14 
Hs00223384_m1 BIRC7 
Hs00261581_m1 CARD6 
Hs01057786_s1 BIRC8 
Hs00370206_m1 DEDD2 
Hs00559441_m1 APAF1 
Hs00985031_g1 BIRC3 
Hs00745222_s1 BIRC4 
Hs00977611_g1 BIRC5 
Hs00236330_m1 FAS 
Hs00181225_m1 FASLG 
Hs00188930_m1 BAD 
 
 
 
 
 
 
 
 
Assay  Gene Symbol 
Hs00608023_m1 BCL2 
Hs00187845_m1 BCL2A1 
Hs00169141_m1 BCL2L1 
Hs00187848_m1 BCL2L2 
Hs00154189_m1 BIK 
Hs00188949_m1 BNIP3L 
Hs00261296_m1 BOK 
Hs00263337_m1 CASP3 
Hs00154250_m1 CASP6 
Hs01017902_m1 CASP10 
Hs00234480_m1 DAPK1 
Hs00193477_m1 HIP1 
Hs01847653_s1 BIRC1 
Hs00153283_m1 NFKBIA 
Hs00153294_m1 RELA 
Hs00174128_m1 TNF 
Hs00175318_m1 IKBKG 
Hs00269428_m1 PEA15 
Hs00601065_g1 TRADD 
Hs00169407_m1 RIPK1 
Hs00705213_s1 HRK 
Hs00234356_m1 TNFSF10 
Hs00538709_m1 FADD 
Hs00366272_m1 TNFRSF10B 
Hs00153439_m1 CFLAR 
Hs00172768_m1 DEDD 
Hs00368095_m1 BCL2L10 
Hs00708019_s1 BCL2L11 
Hs00248075_m1 BBC3 
Hs00203118_m1 PYCARD 
Hs00219876_m1 DIABLO 
Hs00212288_m1 BIRC6 
Hs99999905_m1 GAPDH 
Hs99999903_m1 ACTB 
Hs00989502_m1 CHUK 
Hs00968436_m1 REL 
Hs01042313_m1 TNFRSF1A 
Hs01572688_m1 RIPK2 
Hs01063858_m1 IKBKE 
Hs01036137_m1 BCAP31 
Hs01043258_m1 ICEBERG 
Hs01076336_m1 TA-NFKBH 
Hs00609632_m1 BID 
Hs00969291_m1 BNIP3 
Hs01031947_m1 CASP4 
Hs99999086_m1 LTA 
Hs00980365_g1 TNFRSF25 
Hs01011159_g1 CRADD 
Hs00961847_m1 BCL10 
Hs01594281_m1 CASP8AP2 
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Figure Legend 
Figure 1A shows the relationship between cytoplasmic IKKα expression and cancer specific 
survival in patients with Luminal A primary operable invasive ductal breast cancer (P=0.076). 
Figure 1B shows the relationship between cytoplasmic IKKα expression and disease-free 
survival in patients with Luminal A primary operable invasive ductal breast cancer (P=0.029). 
Figure 1C shows the relationship between cytoplasmic IKKα expression and recurrence-free 
survival on tamoxifen in patients with Luminal A primary operable invasive ductal breast cancer 
(P<0.001). 
Figure 1D shows the relationship between nuclear IKKα expression and cancer specific survival 
in patients with Luminal A primary operable invasive ductal breast cancer (P=0.012). 
Figure 1E shows the relationship between nuclear IKKα expression and disease-free survival in 
patients with Luminal A primary operable invasive ductal breast cancer (P=0.066). 
Figure 1F shows the relationship between nuclear IKKα expression and recurrence-free survival 
on tamoxifen in patients with Luminal A primary operable invasive ductal breast cancer 
(P=0.013). 
Figure 1G shows the relationship between total tumour cell IKKα expression and cancer 
specific survival in patients with Luminal A primary operable invasive ductal breast cancer 
(P=0.007). 
Figure 1H shows the relationship between total tumour cell IKKα expression and disease-free 
survival in patients with Luminal A primary operable invasive ductal breast cancer (P=0.009). 
Figure 1I shows the relationship between total tumour cell IKKα expression and recurrence-free 
survival on tamoxifen in patients with Luminal A primary operable invasive ductal breast cancer 
(P<0.001). 
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Figure 2A shows the relationship between cytoplasmic IKKα expression and disease-fee 
survival in patients with ER-positive primary operable invasive ductal breast cancer (P=0.024). 
Figure 2B shows the relationship between cytoplasmic IKKα expression and recurrence-free 
survival on tamoxifen in patients with ER-positive primary operable invasive ductal breast 
cancer (P=0.038). 
Figure 2C shows the relationship between cytoplasmic IKKα expression and cancer specific 
survival in patients with Luminal A primary operable invasive ductal breast cancer (P=0.023). 
Figure 2D shows the relationship between cytoplasmic IKKα expression and disease-free 
survival in patients with Luminal A primary operable invasive ductal breast cancer (P=0.002). 
Figure 2E shows the relationship between cytoplasmic IKKα expression and recurrence-free 
survival on tamoxifen in patients with Luminal A primary operable invasive ductal breast cancer 
(P=0.009). 
 
Figure 3A shows Western blot and plots when expression was quantified by image-J for MCF7 
cells and MDA-MB-231 cells stimulated with LTx. 
Figure 3B shows Western blot for MCF7 and MDA-MB-231 cells treated with lipofectamine 
(C), non-targeting siRNA (NT) and IKKα (IKK) siRNA. 
Figure 3C shows plots for fold change in apoptosis levels in MCF7 cells and MDA-MB-231 
cells treated with lipofectamine (C), non-targeting siRNA (NT) and IKKα (IKK) siRNA.  The 
western blot displayed demonstrates the decrease in expression of IKKα achieved in the cells 
used for the apoptotic assay shown in Figure 3C and also for the cells used in the wst-1 assays 
Figure 4A.   
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Figure 4A shows plots for fold change in cell viability levels in MCF7 cells and MDA-MB-231 
cells treated with lipofectamine (C), non-targeting siRNA (NT) and IKKα (IKK) siRNA.  Refer 
to Figure 3C for western blot demonstrating level of IKKα knock down achieved. 
Figure 4B shows xCELLigence cell index plots for MCF7 cells and MDA-MB-231 cells treated 
with lipofectamine (C), non-targeting siRNA (NT) and IKKα (IKK) siRNA. 
Figure 4C shows volcano plot for change in gene expression in MCF7 cells pretreated with non-
targeting siRNA (NT) or IKK (IKK)siRNA and stimulated with LTx (20ng/ml) for 12 hours. 
Supplementary Figures  
S.Figure 1A and B shows an example of low cytoplasmic and low nuclear IKKα expression. 
S.Figure 1C and D shows an example of high cytoplasmic and high nuclear IKKα expression. 
S.Figure 1E and F shows an example of a negative control. 
 
S.Figure 2A shows western blot displaying a single band of appropriate size (85kDa).  A 
reduction in expression was observed in lysates from IKKα silenced cells but not from 
IKKsilenced cells. 
S.Figure 2b shows paraffin embedded cell pellets treated with siRNA. A reduction in expression 
was observed in cell pellets for IKKα silenced cells but not for IKKsilenced cells compared to 
the control cells. 
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